Talon Private Wealth LLC Invests $780,000 in Elanco Animal Health Incorporated $ELAN

Talon Private Wealth LLC acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 31,676 shares of the company’s stock, valued at approximately $780,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. NewEdge Advisors LLC increased its stake in Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in Elanco Animal Health during the 2nd quarter worth approximately $35,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Elanco Animal Health in the second quarter valued at approximately $38,000. Root Financial Partners LLC lifted its stake in Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after buying an additional 592 shares in the last quarter. Finally, Uniplan Investment Counsel Inc. acquired a new position in shares of Elanco Animal Health in the fourth quarter valued at approximately $41,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Paul Herendeen purchased 10,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were purchased at an average cost of $23.68 per share, with a total value of $236,800.00. Following the transaction, the director directly owned 111,687 shares of the company’s stock, valued at $2,644,748.16. This represents a 9.83% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Robert Vanhimbergen purchased 4,200 shares of the business’s stock in a transaction on Friday, August 7th. The shares were acquired at an average cost of $23.08 per share, for a total transaction of $96,936.00. Following the completion of the transaction, the chief financial officer directly owned 137,516 shares in the company, valued at approximately $3,173,869.28. This represents a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders acquired 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is owned by insiders.

Elanco Animal Health Price Performance

Shares of ELAN opened at $23.19 on Friday. The stock has a market capitalization of $11.59 billion, a P/E ratio of -56.57, a P/E/G ratio of 1.71 and a beta of 1.68. Elanco Animal Health Incorporated has a twelve month low of $18.22 and a twelve month high of $27.98. The company has a 50 day moving average of $24.54 and a 200-day moving average of $23.93. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same quarter in the previous year, the firm posted $0.26 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, equities research analysts forecast that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ELAN. Morgan Stanley increased their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 22nd. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. UBS Group upped their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. TD Cowen increased their target price on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Finally, KeyCorp lifted their price target on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites, improve animal well-being and support productivity in livestock and aquaculture.

The company’s products include vaccines, parasiticides, antibiotics, animal health pharmaceuticals and nutritional supplements. Its companion animal portfolio serves dogs and cats, while its livestock business provides products for cattle, poultry, swine and aquaculture operations.